3-D Matrix, Ltd.
Stock Price Chart
2026/10/09 12:26 UpdatedPrice Trend
2026/10/09 12:26 UpdatedPrice & Trading Details
2026/10/09 12:26 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2016/03/14 | ¥12.01 | ¥-46.25 | -485.0% |
| 2015/09/06 | ¥12.44 | ¥-21.12 | -269.8% |
| 2015/03/12 | ¥36.61 | ¥-20.49 | -156.0% |
| 2014/12/10 | ¥32.81 | ¥-24.07 | -173.4% |
Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
iShares Trust-iShares International Small-Cap Equity Factor ETF
|
44.2K | 0.00% | |
|
ProShares Trust-ProShares Smart Materials ETF
|
5.9K | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Curio Wealth, LLC
|
38.9K | 0.00% |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,314M | ¥4,589M | ¥6,934M | ¥10,886M |
| Gross Profit | ¥1,288M | ¥3,086M | ¥4,425M | ¥8,572M |
| Operating Income | -¥3,158M | -¥2,117M | -¥1,156M | ¥1,336M |
| Pretax Income | -¥2,383M | ¥59M | -¥2,405M | ¥4,170M |
| Net Income | -¥2,446M | -¥256M | -¥2,501M | ¥4,156M |
| EPS | -¥40.64 | -¥3.49 | -¥22.68 | ¥34.89 |
| Operating Margin | -136.48% | -46.13% | -16.67% | 12.27% |
| Balance Sheet | ||||
| Total Assets | ¥5,826M | ¥5,886M | ¥6,513M | ¥9,796M |
| Total Equity | ¥525M | ¥353M | ¥2,216M | ¥6,796M |
| Total Liabilities | ¥5,301M | ¥5,533M | ¥4,297M | ¥2,999M |
| Cash | ¥1,171M | ¥1,364M | ¥1,580M | ¥2,831M |
| Interest-bearing Debt | ¥4,374M | ¥4,174M | ¥2,941M | ¥600M |
| Equity Ratio | 9.01% | 6.00% | 34.03% | 69.38% |
| D/E Ratio | 8.33 | 11.81 | 1.33 | 0.09 |
| Cash Flow | ||||
| Operating CF | -¥4,585M | -¥1,900M | -¥1,714M | ¥397M |
| Investing CF | -¥82M | -¥30M | -¥33M | -¥42M |
| Financing CF | ¥2,956M | ¥2,063M | ¥2,014M | ¥786M |
| Free CF | -¥4,604M | -¥1,904M | -¥1,726M | ¥369M |
| Efficiency | ||||
| ROE | -466.10% | -72.32% | -112.86% | 61.15% |
| ROA | -41.99% | -4.34% | -38.40% | 42.43% |
Latest IR Information
-
Q1 2027 Financial Summary (Consolidated) [Japanese GAAP]
For the first quarter of the April 2027 term, consolidated net sales were 3,225 million yen, operating income was 494 million yen, ordinary income was 342 million yen, and net income attributable to owners of the parent was 302 million...
Read more -
Unknown
Announced the financial results for the third quarter of FY2024, with sales of 10.5 trillion yen (YoY +8.2%), and net income is unknown. Details by segment and region are also provided.
Read more -
Share Option Issuance Confirmation | July 22, 2026
Three D Matrix Co., Ltd. issued 5,178 new stock acquisition rights (warrants) on July 22, 2026, with an allotment price of 39,400 yen per warrant. The rights are allocated to directors and employees, with the purpose of issuance not specified.
Read more -
Notice of Stock Option and New Share Subscription Rights Issuance
The Company has resolved to issue 517,800 stock subscription rights to directors and employees for the purpose of providing mid- to long-term incentives. The total issuance represents approximately 0.4% of the issued shares, with an exercise period from July 22,...
Read more -
Details of the 2026 Full-Year Financial Results and Medium-Term Management Plan ｜ July 17, 2026
The full-year financial results for the fiscal year ending April 2026 show sales figures that are unknown, with operating profits in the U.S., Europe, and Japan being either positive or negative. The medium-term plan aims for increased sales by April...
Read more
Latest News (5 items)
Company Information
About
3-D Matrix, Ltd. developing, manufacturing, and selling self-assembling peptide technology in Japan and internationally. It offers PuraMatrix, a self-assembling peptide hydrogel for use in the regenerative medicine, cell therapy, drug delivery systems, and other uses in various fields; and surfactant-like peptide, as well as High Concentration PuraMatrix, a high concentration hydrogel; and GMP Grade PuraMatrix. The company was incorporated in 2004 and is based in Tokyo, Japan.
